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OBJECTIVES This study evaluated the cost-effectiveness of administering prophylactic intravenous (IV)
amiodarone therapy to patients undergoing cardiac surgery according to their predicted risk
of postoperative atrial fibrillation.
BACKGROUND Atrial fibrillation (AF) is a common complication of cardiovascular surgery that is associated
with a significant increase in hospitalization costs. Intravenous amiodarone has been shown
to decrease the incidence of postoperative AF.
METHODS All 8,709 patients who underwent coronary artery bypass grafting (CABG), 1,217 patients
who underwent valve replacement and 624 patients who underwent CABG and valve
replacement procedures (CABG  valve) from January 1, 1994, to June 30, 1999, at Emory
University Hospitals were studied. Models predicting the risk of AF were developed using
logistic regression; linear regression was used to estimate the influence of AF on hospital-
ization costs. Cost-effectiveness was evaluated for patient subsets identified according to their
predicted risk of AF.
RESULTS Postoperative AF rates were 17.7% for CABG, 24.6% for valve and 33.8% for CABG 
valve. Using $5,000 as an acceptable cost per episode of atrial fibrillation averted, prophylactic
IV amiodarone in CABG patients was not found to be cost-effective. Therapy would be
recommended for roughly 5% of valve patients with a predicted risk of atrial fibrillation
45%, and roughly two thirds of CABG valve patients who have a predicted risk of30%.
CONCLUSIONS Cost-effectiveness of prophylactic IV amiodarone varies according to type of surgery and the
predicted risk of atrial fibrillation. Older patients undergoing valve replacement, particularly
those with a history of chronic obstructive pulmonary disease, and those undergoing
concomitant CABG are likely to be the most appropriate candidates for IV amiodarone
therapy in the perioperative period. (J Am Coll Cardiol 2002;40:737–45) © 2002 by the
American College of Cardiology Foundation
Atrial fibrillation (AF) occurs frequently after cardiac sur-
gery, with reported incidences ranging from 20% to 50% of
cases (1–7). Several strategies have been used to decrease the
risk of this complication. The use of an oral amiodarone
chlorhydrate (Cordarone) load before surgery has been
shown to decrease the postoperative risk of AF (8). How-
ever, the difficulties associated with rapidly loading patients
orally have raised the question of whether this dosing could
be accomplished more readily with an intravenous (IV) load.
This question was addressed in the Amiodarone Reduction
in Coronary Heart (ARCH) trial, which showed that IV
amiodarone could reduce the incidence of AF by 26% (9).
The question remaining after the ARCH study is whether
it is reasonable to give IV amiodarone to all patients having
cardiac surgery or whether a more cost-effective approach
would be to target this therapy to patients at or above a
certain level of predicted risk of AF. The purpose of this
study was to evaluate the cost-effectiveness of targeting IV
amiodarone therapy to patients at varying levels of risk.
METHODS
Patient population. Data from 10,550 patients who un-
derwent coronary artery bypass grafting (CABG) (n 
8,709), valve replacement (n  1,217) and combined
CABG and valve replacement procedures (CABG  valve)
(n  624) at Emory University Hospitals between January
1, 1994 and June 30, 1999 were used to develop two models
for each patient population: 1) a model to predict the
occurrence of AF and 2) a model to estimate the influence
of AF on hospitalization costs. In addition, data from
25,975 patients who underwent coronary or valve surgery
between 1980 and 1995 were used to estimate the influence
of postoperative atrial fibrillation on five-year survival.
Patients with a history of AF were excluded from the study.
Definitions. Emergent procedure: performed in the setting
of hemodynamic instability, acute ischemia or infarction.
Defined by patient history: hypertension, diabetes, severity of
angina, previous myocardial infarction (MI). Angina was
categorized according to the Canadian Cardiovascular So-
ciety Classification (10). Congestive heart failure was cate-
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gorized according to the New York Heart Association
criteria (11).
Data collection and statistical analysis. This study is a
retrospective analysis of prospectively collected data. Base-
line demographic, clinical, angiographic and surgical char-
acteristics, including complications, were recorded prospec-
tively on standardized forms and entered into a
computerized database. Similarly, follow-up outcome data
were collected at one year and every five years postprocedure
and during all cardiac rehospitalizations at Emory Univer-
sity Hospitals and entered into the same computerized
database.
DEVELOPMENT OF THE MODELS TO PREDICT AF. Multiva-
riable logistic regression was used to examine the influence
of a variety of demographic, clinical, angiographic and
surgical characteristics on the development of postoperative
AF. Separate models were fit for each group (CABG, valve
replacement, CABG  valve). Multiple imputation, imple-
mented in S-plus, was used to impute missing covariate
values. Potential nonlinear effects of each of the continuous
predictor variables (age, ejection fraction, cross-clamp time,
bypass time) on AF were checked using restricted cubic
spline functions (piecewise polynomials). The ability of the
logistic regression models to discriminate among patients
with respect to their outcomes was measured using the
c-index, equivalent to the area under the receiver-operating
characteristic curve. The models were validated internally
using bootstrap analysis (150 bootstrap samples).
COST AND COST-EFFECTIVENESS ANALYSIS. Hospital
charges were obtained from the UB-92 formulation of the
hospital bill. Charges were reduced to costs using depart-
mental cost-to-charge ratios. Professional charges were
obtained from Current Procedural Terminology codes,
which were converted to relative value units (RVUs) using
the Resource Based Relative Value Scale (12); RVUs were
summed and converted to dollars using the Medicare
conversion factor. Hospital and professional costs were
added together yielding total hospitalization costs.
Linear regression was used to estimate the influence of
AF on total hospitalization costs after adjusting for the
effects of significant clinical and demographic factors. In
addition to an indicator for the development of postopera-
tive AF, candidate predictors in these models included
demographic, clinical and procedural characteristics
Decision analytic models (13) were developed to evaluate
the cost-effectiveness of targeted IV amiodarone therapy for
each of the three types of heart surgery patients based on
in-hospital cost and event rate data and corresponding
models previously described, published efficacy of IV ami-
odarone (26% reduction in atrial fibrillation rate) from the
ARCH trial (9) and an assumed cost of amiodarone of $973
(1 g per day for two days). Results from the AF and
cost-prediction models were used to provide patient-level
inputs into the decision model used to evaluate cost-
effectiveness. The model was specified by a set of definitions
and equations that are available upon request. Sensitivity
analyses were performed to assess the influence of varying
the cost of therapy, efficacy of therapy and the cut-off
probability of AF for initiating therapy on the cost-
effectiveness ratio.
LONG-TERM COST-EFFECTIVENESS. Cost-effectiveness was
also estimated, taking a longer-term perspective in terms of
cost per quality-adjusted life year gained. This involved
making assumptions about the effect of postoperative AF on
future costs, appropriate discount rate, utility and effect of
events on utility, as well as the impact of the prevention of
postoperative AF on future survival. Five-year survival in
patients with and without postoperative AF was estimated
using Cox proportional hazards regression (14), adjusting
for the mean (continuous) and mode (categorical) of all
covariates included in the model. Separate analyses were
performed on data for 21,349 CABG patients, 3,275 valve
replacement patients and 1,351 CABG  valve patients
who underwent surgery between 1980 and 1995.
RESULTS
Clinical and angiographic characteristics of the patient
populations are presented in Table 1. Valve replacement
patients were the youngest, whereas CABG  valve pa-
tients were the oldest. The percentage of women was
highest for valve surgery and lowest for isolated CABG.
Previous MI was common in patients undergoing CABG.
Hypertension was common overall although more common
in CABG patients. Diabetes was most common in patients
undergoing isolated CABG and least common in isolated
valve replacement patients. Most of the cases were elective.
Comorbidity of previous stroke, chronic obstructive pulmo-
nary disease and renal insufficiency were noted in a minority
of patients. Fewer than one in four patients was a current
smoker. Ejection fraction was in the low-normal range on
average. There were considerably more severe coronary
obstructions in the CABG patients.
Mortality ranged from 2.6% in isolated CABG patients
to 11.7% in CABG  valve patients. Atrial fibrillation
occurred in 17.7% of isolated CABG cases, 24.6% of
isolated valve cases and in 33.8% of CABG  valve cases.
After adjusting for covariates, AF was associated with a
Abbreviations and Acronyms
AF  atrial fibrillation
ARCH  Amiodarone Reduction in Coronary
Heart trial
CABG  coronary artery bypass grafting
CABG  valve  combined coronary artery bypass graft
and valve replacement
IV  intravenous
MI  myocardial infarction
QALY  quality-adjusted life year
RVU  relative value unit
valve  valve replacement
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3.4-, 3.3- and 6.4-day increase in postprocedural length of
stay for CABG, valve and CABG  valve patients, respec-
tively.
Multivariate predictors of the occurrence of postoperative
AF are shown for CABG, valve and CABG  valve
patients in Table 2. For CABG patients, variables associ-
ated with a significant increase in the risk of AF were
increasing age, increasing bypass time, male gender and
previous MI. The c-index for this model was 0.68 (the
validated c-index was also 0.68), suggesting a moderate
ability to predict the occurrence of postoperative AF.
Factors associated with a significant increase in the risk of
postoperative AF for valve patients were increasing age,
chronic obstructive pulmonary disease and smoking status,
which had a paradoxical effect whereby current smokers
were found to have a significantly lower risk of AF than
never smokers. This model had a c-index of 0.67 (validated
c-index of 0.66). For CABG  valve patients, only two
factors, increasing age and renal failure, were independently
associated with an increased risk of postoperative atrial
Table 1. Clinical and Angiographic Characteristics
Characteristic
Valve Only
p Value
CABG Only
p Value
CABG  Valve
p Value
AF
(n  299)
No AF
(n  918)
AF
(n  1541)
No AF
(n  7168)
AF
(n  211)
No AF
(n  413)
Age 63  13 55  15 0.001 68  9 62  11 0.001 71  9 67  11 0.001
Female (%) 42 46 0.209 27 26 0.618 33 36 0.436
Previous MI (%) 12 10 0.458 61 58 0.101 39 41 0.737
Hypertension (%) 49 43 0.105 69 65 0.002 66 61 0.204
Diabetes (%) 13 11 0.272 30 32 0.240 25 23 0.615
Previous CABG (%) 8 8 0.728 11 11 0.640 18 26 0.042
Previous PTCA (%) 3 3 0.583 23 23 0.981 13 17 0.128
Emergent/urgent status (%) 4 7 0.093 15 14 0.213 9 9 0.754
Hyperlipidemia (%) 30 26 0.290 64 69 0.001 53 57 0.403
Previous stroke (%) 10 12 0.362 12 9 0.025 13 16 0.304
COPD (%) 14 8 0.015 15 15 0.799 21 17 0.405
Renal insufficiency (%) 9 9 0.845 9 7 0.012 20 12 0.039
Smoking status (%) 0.002 0.001 0.037
Current 10 19 17 26 14 22
Former 38 33 51 44 47 42
Never 51 48 32 30 39 36
Ejection fraction 52  12 55  11 0.069 50  13 51  12 0.357 51  12 50  14 0.548
Number of diseased vessels (%) 0.510 0.004 0.883
0 82 87 2 3 7 6
1 8 6 9 11 23 25
2 3 2 22 23 28 23
3 3 3 45 47 25 29
Left main 3 1 23 18 18 17
P values in table are for comparing atrial fibrillation versus no atrial fibrillation within each surgery group. All p  0.001 for testing for differences across three surgery groups
except previous stroke (p  0.003).
AF  atrial fibrillation; CABG  coronary artery bypass grafting; COPD  chronic obstructive pulmonary disease; MI  myocardial infarction; PTCA  percutaneous
transluminal coronary angioplasty.
Table 2. Predictors of Postprocedural Atrial Fibrillation
Characteristic Wald 2 df p Value Odds Ratio 95% CI
CABG patients*
Age 401.07 1 0.0001 1.84 1.73–1.95
Gender 5.84 1 0.016 0.85 0.75–0.97
Bypass time 14.64 1 0.0001 1.03 1.02–1.05
Previous MI 5.31 1 0.021 0.87 0.77–0.98
Valve replacement patients†
Age 50.81 1 0.0001 1.44 1.30–1.60
COPD 5.16 1 0.023 1.60 1.07–2.41
Smoker 4.98 2 0.083
Former vs. never 0.91 0.68–1.24
Current vs. never 0.59 0.37–0.94
Combined CABG and valve replacement patients‡
Age 23.44 1 0.0001 1.53 1.29–1.83
Renal insufficiency 8.82 1 0.003 1.97 1.26–3.08
*8,709 patients with 1,541 events; c-index  0.676 (validated c-index  0.675); †1,217 patients with 299 events; c-index 
0.665 (validated c-index  0.659); ‡624 patients with 211 events; c-index  0.645 (validated c-index  0.643).
CABG  coronary artery bypass grafting; CI  confidence interval; df  degrees of freedom; COPD  chronic obstructive
pulmonary disease; MI  myocardial infarction.
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fibrillation. This model had a c-index of 0.65 (validated
c-index of 0.64).
For each of the populations, the linear regression models
revealed that AF was associated with a significant increase
in costs though the estimated magnitude varied. For CABG
patients, AF was associated with an increase of $3,783 
310, for valve patients, AF was associated with a $2,857 
932 increase and the estimated increase in cost for CABG
 valve patients was $4,536  1441.
Tables 3, 4 and 5 present results of cost-effectiveness
analyses for CABG, valve replacement and CABG  valve
patients, respectively. The columns to the far left in each
table present the treatment threshold in terms of the
predicted probability of AF above which therapy with
amiodarone would be given. For CABG patients (Table 3),
assuming a 0% threshold, 100% of the patients would be
treated (column 2), and the event rate would drop from
17.7% (last row of column 3) to 13.1% (first row of column
3). The mean in-hospital cost per patient would also
change, from $23,296 (last row of column 4) to $24,443
(first row of column 4). The average cost per episode of AF
averted (column 5) for the strategy of treating all patients
versus no patients is derived by dividing the difference in
average costs of the two strategies by the difference in the
two AF rates, i.e. ($24,443  $23,296) / (17.7  13.1) 
$24,934. The incremental cost per episode of AF averted for
a strategy of treating patients at one cutoff level versus the
next highest cutoff level is derived in an analogous manner.
Column 6 shows the incremental (or marginal) cost per
episode averted. Progressing from the bottom of column 6
towards the top, entries in column 6 describe the additional
costs associated with preventing an event for patients in the
next lowest level of risk. For example, the incremental cost
per event averted moving from a 30% to a 25% probability
of AF threshold for treatment is $17,479.
There is a great degree of variability in cost-effectiveness
as the probability of AF in the targeted population varies.
As the threshold probability of developing AF above which
patients will receive therapy is increased, the risk of AF in
the targeted patients rises, while the cost-effectiveness ratio
falls. Because of the competition for limited healthcare
resources, the consideration of additional healthcare expen-
ditures should be based on the evaluation of whether the
additional expense is worthwhile given the benefits accrued;
therefore, it is the incremental cost-effectiveness ratios that
must be evaluated with respect to their acceptability. The
Table 3. Cost-Effectiveness Among CABG Only Patients Assuming 26% Effectiveness and
$973 Cost of Intravenous Amiodarone Therapy (1 g per day/2 days)
Treatment
Threshold*
Patients
Treated (%)
AF Rate
(%)
Mean Cost
($)
Average Cost/
Event Averted ($)†
Incremental Cost/
Event Averted ($)†
0 100 13.1 24,443 24,934 55,854
10 77.7 13.5 24,210 21,859 34,087
15 55.5 14.2 23,967 19,346 25,224
20 36.4 15.1 23,748 17,388 20,540
25 21.3 16.0 23,569 15,786 17,479
30 10.6 16.7 23,435 14,450 15,406
35 4.2 17.3 23,353 13,256 13,864
40 1.5 17.5 23,317 12,340 12,696
45 0.5 17.6 23,302 11,626 11,789
50 0.1 17.7 23,297 10,938 10,938
100 0 17.7 23,296 — —
*The treatment threshold is the predicted risk of atrial fibrillation (AF) above which amiodarone therapy would be initiated;
†an event is an episode of postoperative AF.
CABG  coronary artery bypass grafting.
Table 4. Cost-Effectiveness Among Valve Replacement Only Patients Assuming 26%
Effectiveness and $973 Cost of Intravenous Amiodarone Therapy (1 g per day/2 days)
Treatment
Threshold*
Patients
Treated (%)
AF Rate
(%)
Mean Cost
($)
Average Cost/
Event Averted ($)†
Incremental Cost/
Event Averted ($)†
0 100 18.2 32,121 12,375 43,011
10 91.7 18.4 32,045 11,507 27,061
15 78.0 18.8 31,924 10,303 18,658
20 60.6 19.6 31,778 8,988 13,687
25 44.6 20.5 31,649 7,891 10,603
30 32.2 21.4 31,554 7,117 8,626
35 19.1 22.5 31,458 6,297 7,179
40 9.1 23.5 31,389 5,490 5,990
45 3.5 24.1 31,352 4,804 5,089
50 1.1 24.4 31,336 4,219 4,219
100 0 24.6 31,330 — —
*The treatment threshold is the predicted risk of atrial fibrillation (AF) above which amiodarone therapy would be initiated;
†an event is an episode of postoperative atrial fibrillation.
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incremental cost per episode of AF averted for CABG
patients ranged from $10,938 for the treatment of the
highest-risk patients to $55,854 for the treatment of the
lowest-risk patients. For valve replacement patients, the
incremental cost per episode of AF prevented ranged from
$4,219 for the highest-risk patients to $43,011 for the
lowest-risk patients. For CABG  valve patients, the
incremental cost per episode of AF prevented ranged from
$69 to $39,698.
A two-way sensitivity analysis on cost of therapy and
effectiveness of therapy for valve replacement placements is
presented in Figure 1. The marginal cost effectiveness for
treating patients with a 25% versus a 30% predicted prob-
ability of AF is shown, as well as isobars of cost from $500
to $1,250 in $250 increments. The x-axis represents the
effectiveness of therapy from 0.20 to 0.60, and the y-axis
represents the cost-effectiveness ratio in dollars per episode
of AF prevented. The cost-effectiveness ratio rises as the
cost of therapy rises. The ratio falls as therapy becomes more
effective.
Table 5. Cost-Effectiveness Among Combined CABG and Valve Replacement Patients
Assuming 26% Effectiveness and $973 Cost of Intravenous Amiodarone Therapy (1 g per day/
2 days)
Treatment
Threshold*
Patients
Treated (%)
AF Rate
(%)
Mean Cost
($)
Average Cost/
Event Averted ($)†
Incremental Cost/
Event Averted ($)†
0 100 25.0 40,784 4,549 39,698
10 99.0 25.0 40,776 4,468 22,009
15 95.4 25.2 49,749 4,213 14,325
20 88.6 25.5 40,704 3,831 9,903
25 76.0 26.2 40,629 3,231 7,178
30 63.8 27.1 40,567 2,722 4,947
35 42.6 28.9 40,478 1,911 3,430
40 27.9 30.3 40,429 1,281 2,346
45 14.4 31.8 40,394 494 1,423
50 9.3 32.4 40,385 69 69
100 0 33.8 40,384 — —
*The treatment threshold is the predicted risk of atrial fibrillation (AF) above which amiodarone therapy would be initiated;
†an event is an episode of postoperative atrial fibrillation.
CABG  coronary artery bypass grafting.
Figure 1. Two-way sensitivity analysis of marginal cost-effectiveness for valve replacement patients, varying the cost and effectiveness of therapy, assuming
a 25% probability of atrial fibrillation cutoff for treatment.
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A two-way sensitivity analysis on cost of therapy and the
probability cutoff for treatment for valve replacement pa-
tients is presented in Figure 2. Therapy is assumed to be
26% effective in preventing episodes of AF. On the x-axis,
the threshold for treatment varies from 0 to 0.50 in terms of
predicted risk of AF. Points are computed as the incremen-
tal cost-effectiveness at each probability of AF threshold
compared to a threshold 2% higher. Again, as the cost of
therapy rises, the cost-effectiveness ratio also rises and as the
probability cutoff for treatment rises, the cost-effectiveness
ratio falls. Thus, a favorable ratio can be achieved by using
a high treatment threshold of predicted risk of AF. How-
ever, as the threshold is raised, the proportion treated will
fall.
For the long-term analysis, Cox regression proportional
hazards model revealed a significant increased hazard of
death for CABG patients who developed postoperative AF
compared to those who did not (hazard ratio: 1.19, 95%
confidence interval [CI]: 1.09 to 1.30) after adjusting for
other significant factors. For valve replacement and CABG
 valve patients, however, no effect of postoperative AF on
long-term survival was found. The inability to estimate a
survival advantage for patients who do not develop AF
renders a long-term cost-effectiveness analysis for valve
replacement and combined CABG and valve patients im-
possible.
For CABG patients, the incremental cost-effectiveness of
targeted therapy measured in cost per quality-adjusted life
year gained is presented in Table 6. The cases for patients
with probability of AF thresholds from 0% to 10% to 45%
to 50% were considered, assuming the cost of therapy to be
$973. From the 26,247 patients who underwent CABG
between 1980 and 1995, the five-year survival was 87.5%
(95% CI 86.5% to 88.3%) without an episode of AF and
85.2% (95% CI 83.8% to 86.6%) with an episode of AF
(p  0.0001). Using an annual 3% discount rate, mean
discounted life years over five years follow-up, adjusted for
the influence of significant covariates using Cox regression,
was 4.18 years for patients without AF and 3.92 years for
patients with AF. No additional survival benefit of an AF
free initial hospitalization was assumed beyond five years. It
was assumed that the cost of medical care after discharge
would be similar in the patients with and without a
postoperative episode of AF, such that any difference in cost
would be reflected in the hospital cost. Five models were
developed. Utility was assumed to decrease for some of the
models by 20% for the first year if there was an episode of
AF, which would reduce quality-adjusted survival to 3.74
years; otherwise, the utility was assumed to remain 1.0.
Therapy that decreases in-hospital events may or may not
decrease future mortality. In the first two models, an event
averted was assumed to increase survival to that of a patient
without an event. In the last three models, the increase in
survival attributed to an event averted was first assumed to
be 50%, then 25% and finally 0% of that in models 1 and 2.
In the final model, the effect of events averted is only to
Figure 2. Two-way sensitivity analysis of marginal cost-effectiveness for valve replacement patients, varying the cost of therapy and the probability cutoff
for treatment, assuming 26% effectiveness.
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improve quality of life in the first year. The cost-
effectiveness ratio varied widely depending on the assump-
tions made. For each model, the cost-effectiveness ratio fell
as the treatment threshold in terms of predicted probability
of AF was raised. The marginal cost-effectiveness compar-
ing a 45% cutoff to a 50% cutoff probability of an event for
the best case (model 2) was $47,553 and for the worst case
(model 1) $174,089 per quality-adjusted life year (QALY).
.
DISCUSSION
By developing a model to predict the occurrence of AF after
cardiac surgery and a second model to estimate the influence
of postoperative AF on hospitalization costs in the same
patients, we were able to perform an analysis examining the
cost-effectiveness of targeting amiodarone therapy to sub-
sets of patients at incrementally lower levels of risk of AF.
We performed these analyses separately for CABG, valve
and CABG  valve patients owing to their different
underlying risk and cost profiles. Because of the inability to
estimate an increased hazard of death for valve replacement
and CABG  valve patients who developed postprocedural
AF, long-term cost-utility analyses could not be performed
for these types of surgical patients. This is unfortunate
because the short-term estimates in terms of cost per
episode of AF prevented are difficult if not impossible to
benchmark against other types of therapy. Nevertheless, the
information presented in Tables 3 through 6, as well as
Figures 1 and 2 can be useful in guiding the decision-
making process regarding which patients should receive
amiodarone. If an acceptable upper limit of cost per episode
of AF averted or QALY gained is known, then all patients
for whom the cost of preventing an event is less than this
upper limit should receive therapy, given the limitations and
assumptions of the models.
Both short-term cost-effectiveness and longer-term cost-
utility analyses suggest that the administration of IV amio-
darone to CABG patients is not cost-effective. Using
$50,000 as the maximum amount that society would be
willing to pay per QALY gained, treatment of the small
fraction of patients at the very highest level of risk results in
cost utility estimates, which are only slightly below $50,000
per QALY under the most favorable assumptions. Esti-
mates of incremental cost per episode of AF averted for the
highest risk CABG patients are $11,000. Although there
are no benchmarks for an acceptable cost per episode of AF
prevented, $5,000 may seem a reasonable amount in terms
of an individual’s willingness to pay to avert an episode of
AF. For valve replacement and CABG  valve patients, if
society were willing to pay $5,000 per episode of AF
prevented, then therapy would be recommended for roughly
5% of valve replacement patients and two thirds of CABG
 valve patients, assuming underlying rates of AF equal to
those observed for this study. If the incidence of AF is
higher than that observed in this study, assuming that the
overall covariate effects for the prediction of AF remained
the same, the proportion of patients treated at any given
predicted probability threshold would increase. An analysis
based on modified logistic regression models, for which the
overall incidence of AF was adjusted upwards to 30%, 40%
and 45% for CABG, valve and combined CABG  valve
patients, respectively (by adjusting the intercept while keep-
ing the originally estimated parameters for the covariate
effects in the logistic regression models), yielded marginal
cost-effectiveness ratios that differed little from those in
presented here, although the percent of valve patients who
would be treated at a 45% predicted probability of AF
threshold increased to 40% and the percent of combined
CABG and valve patients who would be treated at a 30%
threshold was 87% (results not presented). Nomograms are
presented online in the Appendix that may be used, with
some caution, to evaluate the probability of developing
postoperative AF for populations with both the observed
and adjusted (higher) underlying risk of AF. The nomo-
grams may be used to predict risk in individual patients.
Accordingly, for a 50-year-old patient undergoing CABG
Table 6. Marginal Cost-Utility Analysis for CABG Patients Assuming 26% Effectiveness of Therapy, 3% Discount Rate and $973
Cost of Therapy
Model specification Model 1 Model 2 Model 3 Model 4 Model 5
Effect of event on utility in first year None 20% 20% 20% 20%
Effect of event averted on long-term mortality* 100% 100% 50% 25% 0%
Marginal Cost/QALY Gained ($)
0%–10% treatment threshold 824,786 225,292 260,928 283,337 309,957
10%–15% treatment threshold 503,357 137,493 159,241 172,917 189,163
15%–20% treatment threshold 372,477 101,743 117,836 127,956 139,978
20%–25% treatment threshold 303,310 82,850 95,955 104,196 113,985
25%–30% treatment threshold 258,109 70,503 81,655 88,668 96,998
30%–35% treatment threshold 227,504 62,143 71,973 78,154 85,497
35%–40% treatment threshold 204,720 55,919 64,765 70,327 76,934
40%–45% treatment threshold 187,484 51,212 59,312 64,406 70,457
45%–50% treatment threshold 174,089 47,553 55,075 59,805 65,423
*100% indicates that an episode of atrial fibrillation (AF) averted is assumed to increase survival to that of a patient without AF; 0%, that an episode of AF averted does not increase
survival.
CABG  coronary artery bypass grafting; QALY  quality-adjusted life year.
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 valve surgery with no history of renal insufficiency, the
predicted risk of AF would be 16%. For this patient,
amiodarone would probably not be cost-effective. However,
for a 60-year old patient with renal insufficiency undergoing
CABG valve surgery, the predicted risk would be 37%. In
this patient, amiodarone therapy may be considered cost-
effective.
AF is a common occurrence after cardiac surgery, with
estimates of incidence ranging from approximately 20% to
50% (1–7). Atrial fibrillation has been shown to be associ-
ated with prolonged length of hospital stay in this study as
well as in previous studies (1,2,15). In this study we have
shown, as have Aranki et al. (1), that AF is associated with
increased hospital costs. Although the heart rate of AF can
generally be easily controlled pharmacologically and AF can
be converted to sinus rhythm both pharmacologically as well
as by electrical cardioversion, AF tends to recur. Further-
more, AF may be complicated by thromboembolic events.
Thus, there would seem to be a role for effective prophy-
lactic therapy. This was examined in a randomized trial of
oral amiodarone by Daoud et al. (8). These investigators
reported a decrease in the incidence of AF after coronary
surgery from 32 of 64 (50%) in the control group to 16 of 64
(25%) in the group who received several days of oral
amiodarone pre-operatively. Because of the logistical diffi-
culty of administering amiodarone orally over several days,
IV amiodarone is a more practical alternative. The efficacy
of IV amiodarone in preventing postoperative AF was
studied in the ARCH trial (9). Patients were treated with
1 g per day of IV amiodarone for two days beginning within
3 h of entering the surgical intensive care unit. Atrial
fibrillation was noted in 67 of 142 (47%) patients on placebo
versus 56 of 158 (35%) on amiodarone (p  0.01), a 26%
reduction in risk. Because amiodarone was clearly effective
in the ARCH trial, the important question of whether all
patients should be treated or whether therapy should be
targeted to patients at higher risk was addressed in the
present cost-effectiveness analysis.
Although this study takes a societal perspective overall,
hospital costs had a hospital perspective and professional
costs a payer perspective, which were used as proxies for
societal costs. The cost-effectiveness ratio should be from a
societal perspective because it is the responsibility of society
as a whole to prevent cardiovascular events because society
would have to pay the cost of these events (16). However,
the hospital would have to pay the cost of the drug and,
depending on reimbursement scheme, may derive little or
no benefit from events prevented (17).
Study limitations. This study was limited by the moderate
ability of the logistic regression models to predict the
occurrence of postoperative AF (c-indexes 0.65–0.68). An
improved ability to identify high-risk patients would result
in more favorable cost-effectiveness ratios. This study is also
limited by the assumption that costs beyond the initial
hospitalization are equivalent in patients who do and do not
develop postoperative AF. If AF also increases costs post-
discharge, the cost-effectiveness of any prophylactic treat-
ment would increase.
The extension of the in-hospital cost-effectiveness anal-
ysis to a long-term cost-utility analysis involved multiple
additional assumptions, some of which are not verifiable.
The cost-effectiveness ratio may be quite sensitive to these
assumptions, as Table 6 suggests. However, with cost-
effectiveness expressed in cost per quality-adjusted life year
gained, it is possible to benchmark the cost-effectiveness of
this therapy against other forms of therapy; this is not
possible when measuring cost-effectiveness in terms of cost
per episode of AF prevented.
On the other hand, the cost-effectiveness ratios expressed
in cost per event averted were highly data driven, and event
rates and costs (exclusive of drug costs) were based on actual
data. Drug efficacy was based on the literature (8,9). Drug
efficacy and costs were the two primary variables examined
by sensitivity analysis.
Another potential limitation is the assumption that the
efficacy of the drug is independent of the probability of an
event. Perhaps in low-risk patients it prevents a lower or a
higher proportion of events. Two additional assumptions
underlying this cost-effectiveness model are that 1) the cost
of an episode of AF in treated patients is equal to the cost
of an episode of AF in untreated patients and 2) the cost of
AF in high-risk patients is equal to that in low-risk patients.
CONCLUSIONS
Through the examination of patient level data and creating
a risk profile, the ability to examine cost-effectiveness
according to predicted level of risk has been demonstrated.
Although a similar approach has been used previously in a
study of lipid lowering (18) and the use of platelet antago-
nists in the setting of high-risk percutaneous coronary
intervention (19), this is the first study to examine the
cost-effectiveness of targeting patients undergoing cardiac
surgery for IV amiodarone treatment according to their
predicted level of risk using inputs derived from an empirical
data set. One other study reported advantages of a selective
approach for the prevention of AF after coronary surgery
using a retrospective analysis of data from a clinical trial
comparing sotalol versus placebo, although a formal cost-
effectiveness analysis was not conducted (20).
Although this study was based on a single center experi-
ence, the population resembled that seen in clinical trials
and registry studies (1–9). This study has shown quantita-
tively and in a real patient population what is often stated:
As the level risk rises, therapy to decrease events can become
more cost-effective. From a societal or policy standpoint,
studies such as this may help in the development of
informed guidelines for the use of expensive therapies.
Although application of these results to decision making for
individual patients must be undertaken with some caution,
this study shows that for low-risk patients, IV prophylactic
amiodarone probably is not cost-effective, whereas for
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higher risk patients, particularly older patients undergoing
valve surgery or patients undergoing CABG  valve sur-
gery, perioperative IV amiodarone may be considered cost-
effective in preventing AF.
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APPENDIX
Nomogram: CABG Patients
1. Find points for each predictive factor:
Age Points Gender Points Prior MI Points Bypass Time Points
20 0 Female 0 No 0 0 0
30 14 Male 4 Yes 3 50 4
40 29 100 8
50 43 150 12
60 57 200 16
70 71 250 20
80 86 300 24
90 100 350 28
400 32
2. Add up points for all predictive factors:
3. Look up risk corresponding to total points:
17.7% Overall Risk 30% Overall Risk
Points Probability of Atrial Fibrillation Points Probability of Atrial Fibrillation
18 0.02 3 0.02
27 0.03 13 0.03
33 0.04 20 0.04
37 0.05 26 0.05
53 0.10 43 0.10
62 0.15 54 0.15
70 0.20 62 0.20
75 0.25 69 0.25
81 0.30 75 0.30
85 0.35 80 0.35
90 0.41 85 0.40
94 0.45 90 0.45
98 0.50 95 0.50
102 0.55 99 0.55
106 0.60 104 0.60
109 0.65
115 0.70
121 0.75
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Nomogram: Valve Replacement Patients
1. Find points for each predictive factor:
Age Points COPD Points Smoking Status Points
20 0 No 0 Current 0
30 13 Yes 16 Former 15
40 25 Never 18
50 38
60 50
70 62
80 75
90 88
100 100
2. Add up points for all predictive factors:
3. Look up risk corresponding to total points:
24.6% Overall Risk 35% Overall Risk
Points Probability of Atrial Fibrillation Points Probability of Atrial Fibrillation
4 0.05 4 0.10
30 0.10 22 0.15
45 0.15 36 0.20
57 0.20 47 0.25
67 0.25 57 0.30
76 0.30 66 0.35
83 0.35 74 0.40
91 0.40 82 0.45
98 0.45 90 0.50
104 0.50 98 0.55
111 0.55 106 0.60
118 0.60 114 0.65
123 0.70
133 0.75
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Nomogram: Combined CABG and Valve Replacement Patients
1. Find points for each predictive factor:
Age Points Renal Insufficiency Points
20 0 No 0
30 13 Yes 20
40 25
50 37
60 50
70 63
80 75
90 88
100 100
2. Add up points for all predictive factors:
3. Look up risk corresponding to total points:
33.8% Overall Risk 45% Overall Risk
Points Probability of Atrial Fibrillation Points Probability of Atrial Fibrillation
21 0.10 7 0.10
34 0.15 21 0.15
45 0.20 31 0.20
53 0.25 39 0.25
60 0.30 47 0.30
67 0.35 53 0.35
73 0.40 59 0.40
79 0.45 65 0.45
85 0.50 71 0.50
91 0.55 77 0.55
97 0.60 83 0.60
103 0.65 89 0.65
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